
About Higlance Laboratories Private Limited
Data last updated:
Higlance Laboratories Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 June 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24239DL2003PTC120847. Its GSTIN is 07AABCH2836H1ZQ (Delhi). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹6 Cr and a paid-up capital of ₹6 Cr. It is led by directors including Sanjay Kumar Singh (Managing Director) and Ajay Singh (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 1204 Hemkunt Chambers 89 Nehru Place, New Delhi, Delhi, India – 110019.
As per the financials filed for FY 2025, the company reported a revenue of ₹75.98 Cr, a growth of 7% compared to the previous year. For the same year it recorded a net profit of ₹6.26 Cr (net margin 8.2%) and EBITDA of ₹11.94 Cr (EBITDA margin 15.7%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 11% over five years.
The company has about 406 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: HiGlance Laboratories and HiGlance. As per MCA filings, the company has open charges of ₹1.86 Cr on record. Court records list 4 cases involving the company, including 4 filed against it; 1 case is pending. The company has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹7.99 Cr; the latest was in September 2011. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Vapi Care Pharma Private Limited with revenue of ₹76.81 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 6 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website higlance.com.
Company details
Contact details
Higlance Laboratories Private Limited's registered office is in New Delhi, Delhi. Its website is higlance.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address1204 Hemkunt Chambers 89 Nehru Place, New Delhi, Delhi, India – 110019
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Higlance Laboratories Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Higlance Laboratories operates two associated brands: HiGlance Laboratories and HiGlance. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures pharmaceutical, vitamins, and nutrient products for health-conscious consumers and markets. | higlance.com | |
| Pharmaceutical production and export of medicines for various health issues from India. | higlance.ru |
Business activity
The main business activity of Higlance Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Higlance Laboratories Private Limited, buy the company report.
Financials of Higlance Laboratories Private Limited
FY 2024 filings availableHiglance Laboratories Private Limited reported revenue of ₹75.98 Cr (up 7% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 7% growth in the latest year. EBITDA rose 24% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.94 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹6.26 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.7% | ||||
| Net Profit Margin | 8.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Higlance Laboratories Private Limited, buy the company report.
Board of directors of Higlance Laboratories Private Limited
Higlance Laboratories has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kalawati Devi | Director | 11 Jun 2003 | 23 Years 5 Months | Current |
| Ajay Singh | Whole-Time Director | 11 Jun 2003 | 23 Years 5 Months | Current |
| Sanjay Kumar Singh | Managing Director | 11 Jun 2003 | 23 Years 5 Months | Current |
Peer comparison
Higlance Laboratories Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vapi Care Pharma Private Limited | ₹76.81 Cr (FY 2025) | -11.0% | Vapi, Valsad, Gujarat, India | |||
| Eskag Pharma Pvt Ltd | ₹76.72 Cr (FY 2024) | 0.0% | Kolkata, West Bengal, India | |||
| Mercury Laboratories Limited | ₹76.17 Cr (FY 2025) | -1.0% | Mumbai, Maharashtra, India | |||
| Vovantis Laboratories Private Limited | ₹76.05 Cr (FY 2025) | 67.0% | Vadodara, Gujarat, India | |||
| Higlance Laboratories Private Limitedthis company | ₹75.98 Cr (FY 2025) | ₹6.26 Cr | 8.2% | 7.0% | 406 | New Delhi, Delhi, India |
| Vital Therapeutics and Formulations Private Limited | ₹75.96 Cr (FY 2024) | 2.0% | Hyderabad, Telangana, India | |||
| Bennet Pharmaceuticals Limited | ₹75.82 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Mccoy Pharma Private Limited | ₹75.62 Cr (FY 2024) | -30.0% | Boisar, Maharashtra, India |
To see the full peer comparison of Higlance Laboratories Private Limited, buy the company report.
Auditor
Higlance Laboratories Private Limited is audited by Naveen Jain & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Naveen Jain & Co. | FY 2024 | 010358N |
Shareholding
The shareholding of Higlance Laboratories Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Higlance Laboratories Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 Oct 2006 | 10028203 | State Bank of India | ₹1.86 Cr | Open |
To see the full charge records of Higlance Laboratories Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Higlance Laboratories Private Limited has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹7.99 Cr; the latest was in September 2011.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2011 | Funding round | ₹3 Cr | Investors: an individual |
| Nov 2006 | Funding round | ₹4.99 Cr | Investors: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Higlance Laboratories Private Limited has 4 court cases on record: 4 filed against it. 1 case is pending and 3 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 4 | 1 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (COMIP) | Filed against the company by Glenmark Pharmaceuticals Limited | Pending |
| Bombay High Court | Court case (LPETN) | Filed against the company by Glenmark Pharmaceuticals Ltd | Disposed |
| Bombay High Court | Court case (S) | Filed against the company by Aglowmed Ltd. | Disposed |
| High Court of Delhi | Court case (CS(OS)) | Filed against the company by an individual | Disposed |
To see the full case history of Higlance Laboratories Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Higlance Laboratories Private Limited has 4 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 6)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Kambert Machinery Company Private Limited | |||
| Om Distributors | |||
| Premier Drug House | |||
| Electrolab (India) Private Limited | |||
| S K Pharma Machinery Private Limited |
To see the full MSME payment records of Higlance Laboratories Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Higlance Laboratories Private Limited has a workforce of 406 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 406 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Higlance Laboratories Private Limited, buy the company report.
GST
Higlance Laboratories has 3 GST registrations: 3 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AABCH2836H1ZQ | Delhi | Active | 01 Jul 2017 |
| 09AABCH2836H1ZM | Uttar Pradesh | Active | 01 Jul 2017 |
| 10AABCH2836H1Z3 | Bihar | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Higlance Laboratories Private Limited, buy the company report.
Recent activity
Higlance Laboratories Private Limited has 7 board changes on record since 2003: 3 appointments and 4 cessations. The latest: Anishrava Agrawal ceased to be Company Secretary on 31 May 2024.
Frequently asked questions
Higlance Laboratories is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 June 2003 (23+ years old) and is registered under CIN U24239DL2003PTC120847.
Higlance Laboratories has 3 current directors:
- Sanjay Kumar Singh - Managing Director
- Ajay Singh - Whole-Time Director
- Kalawati Devi - Director
The latest financial statements of Higlance Laboratories on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Higlance Laboratories is 07AABCH2836H1ZQ, registered in Delhi. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 09AABCH2836H1ZM (Uttar Pradesh), 10AABCH2836H1Z3 (Bihar).
The CIN (Corporate Identification Number) of Higlance Laboratories is U24239DL2003PTC120847. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Higlance Laboratories has 4 court cases on record: 4 filed against it. 1 is pending.
Higlance Laboratories was incorporated on 11 June 2003, making it 23+ years old. It is registered with the Registrar of Companies, Delhi.
Higlance Laboratories has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹7.99 Cr; the latest was in September 2011.
The peers of Higlance Laboratories by revenue are Vapi Care Pharma Private Limited, Eskag Pharma Pvt Ltd, Mercury Laboratories Limited, Vovantis Laboratories Private Limited, Vital Therapeutics and Formulations Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anishrava Agrawal ceased to be Company Secretary on 31 May 2024. Ajay Singh ceased to be Director on 10 Mar 2018. Sanjay Kumar Singh ceased to be Director on 10 Mar 2018. Higlance Laboratories has 7 board changes on record in total.
Higlance Laboratories has 4 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 6 micro and small suppliers. The latest return was filed on 01 May 2024.
Higlance Laboratories can be reached through the website higlance.com. Its registered office is in New Delhi, Delhi, India.

